Literature DB >> 23774990

Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

Gaiane M Rauch1, Henry M Kuerer, Marion E Scoggins, Patricia S Fox, Ana P Benveniste, Young Mi Park, Sara A Lari, Brian P Hobbs, Beatriz E Adrada, Savitri Krishnamurthy, Wei T Yang.   

Abstract

The clinicopathologic, mammographic, and sonographic findings in patients with pure ductal carcinoma in situ (DCIS) were assessed by estrogen receptor (ER) expression. After institutional review board approval, patients with pure DCIS evaluated from January 1996 to July 2009 with known ER status and available imaging were identified. Images were reviewed as per the ACR BI-RADS(®) lexicon (4th edition). Clinical, pathologic, and imaging characteristics were analyzed by ER status using t test, Chi square test, and Fisher's exact test. Of 1,219 patients with pure DCIS and known ER status identified, 1,187 with complete data were included. Mammography was performed in all 1,187 patients and sonography in 519 (44 %). There were 972 (82 %) patients with ER-positive and 215 (18 %) with ER-negative disease. ER-negative DCIS was more likely to be high grade (93 vs 44 %, p < 0.0001), associated with comedonecrosis (64 vs 29 %, p < 0.0001), and multifocal (23 vs 15 %, p = 0.009). On sonography, ER-negative DCIS was more likely to be visible (61 vs 46 %, p = 0.004), larger (mean size, 2.3 vs 1.6 cm, p = 0.006), and show posterior shadowing (53 vs 28 %, p = 0.006). Mastectomy was more frequently performed for ER-negative DCIS (47 vs 37 %, p = 0.008). Palpable DCIS was visible on sonography in 55 % of cases and mammography in 81 %. Compared with ER-positive palpable DCIS, ER-negative palpable DCIS was larger and more likely to be visible on sonography. Compared with ER-positive noncalcified DCIS, ER-negative noncalcified DCIS was less likely to be visible on mammography. ER-positive and ER-negative pure DCIS have different clinicopathologic and imaging characteristics. ER-negative DCIS is associated with worse prognostic factors than ER-positive DCIS. On sonography, ER-negative DCIS is more frequently visible than ER-positive DCIS, tends to be larger, and more frequently demonstrates posterior shadowing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774990      PMCID: PMC3982796          DOI: 10.1007/s10549-013-2598-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  45 in total

1.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

2.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

3.  Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

Authors:  A Ringberg; L Anagnostaki; H Anderson; I Idvall; M Fernö
Journal:  Eur J Cancer       Date:  2001-08       Impact factor: 9.162

4.  HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy.

Authors:  Laura C Collins; Stuart J Schnitt
Journal:  Mod Pathol       Date:  2005-05       Impact factor: 7.842

Review 5.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.

Authors:  Beth A Virnig; Todd M Tuttle; Tatyana Shamliyan; Robert L Kane
Journal:  J Natl Cancer Inst       Date:  2010-01-13       Impact factor: 13.506

6.  EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.

Authors:  Annette Lebeau; Angela Unholzer; Gudrun Amann; Michaela Kronawitter; Ingo Bauerfeind; Andrea Sendelhofert; Anette Iff; Udo Löhrs
Journal:  Breast Cancer Res Treat       Date:  2003-05       Impact factor: 4.872

Review 7.  Current treatment and clinical trial developments for ductal carcinoma in situ of the breast.

Authors:  Judy C Boughey; Ricardo J Gonzalez; Everett Bonner; Henry M Kuerer
Journal:  Oncologist       Date:  2007-11

8.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Authors:  Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George
Journal:  Lancet Oncol       Date:  2010-12-07       Impact factor: 41.316

9.  Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.

Authors:  Sara A Lari; Henry M Kuerer
Journal:  J Cancer       Date:  2011-05-01       Impact factor: 4.207

10.  Immunohistochemical categorisation of ductal carcinoma in situ of the breast.

Authors:  P Meijnen; J L Peterse; N Antonini; E J Th Rutgers; M J van de Vijver
Journal:  Br J Cancer       Date:  2007-11-27       Impact factor: 7.640

View more
  12 in total

1.  Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma.

Authors:  Jidong Xiao; Yuanquan Zhou; Wenhui Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 2.  A review of the influence of mammographic density on breast cancer clinical and pathological phenotype.

Authors:  Michael S Shawky; Cecilia W Huo; Kara Britt; Erik W Thompson; Michael A Henderson; Andrew Redfern
Journal:  Breast Cancer Res Treat       Date:  2019-06-08       Impact factor: 4.872

3.  Imaging features that distinguish pure ductal carcinoma in situ (DCIS) from DCIS with microinvasion.

Authors:  Hongli Wang; Jinjiang Lin; Jianguo Lai; Cui Tan; Yaping Yang; Ran Gu; Xiaofang Jiang; Fengtao Liu; Yue Hu; Fengxi Su
Journal:  Mol Clin Oncol       Date:  2019-07-03

Review 4.  Ductal Carcinoma in Situ: State-of-the-Art Review.

Authors:  Lars J Grimm; Habib Rahbar; Monica Abdelmalak; Allison H Hall; Marc D Ryser
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

5.  Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence.

Authors:  Gaiane M Rauch; Brian P Hobbs; Henry M Kuerer; Marion E Scoggins; Ana P Benveniste; Young Mi Park; Abigail S Caudle; Patricia S Fox; Benjamin D Smith; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang
Journal:  Ann Surg Oncol       Date:  2015-09-28       Impact factor: 5.344

6.  Radiopathological features predictive of involved margins in ductal carcinoma in situ.

Authors:  D M Layfield; H See; M Stahnke; L Hayward; R I Cutress; R S Oeppen
Journal:  Ann R Coll Surg Engl       Date:  2016-09-23       Impact factor: 1.891

7.  Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Authors:  Mieke Van Bockstal; Kathleen Lambein; Hannelore Denys; Geert Braems; Ann Nuyts; Rudy Van den Broecke; Veronique Cocquyt; Olivier De Wever; Louis Libbrecht
Journal:  Virchows Arch       Date:  2014-06-29       Impact factor: 4.064

8.  Screen-detected ductal carcinoma in situ found on stereotactic vacuum-assisted biopsy of suspicious microcalcifications without mass: radiological-histological correlation.

Authors:  Bartlomiej Szynglarewicz; Piotr Kasprzak; Przemyslaw Biecek; Agnieszka Halon; Rafal Matkowski
Journal:  Radiol Oncol       Date:  2016-04-23       Impact factor: 2.991

9.  Imaging of Noncalcified Ductal Carcinoma In Situ.

Authors:  Ashley Bragg; Rosalind Candelaria; Beatriz Adrada; Monica Huang; Gaiane Rauch; Lumarie Santiago; Marion Scoggins; Gary Whitman
Journal:  J Clin Imaging Sci       Date:  2021-06-16

10.  Early diagnosis of breast cancer from exhaled breath by gas chromatography-mass spectrometry (GC/MS) analysis: A prospective cohort study.

Authors:  Yu Zhang; Lei Guo; Zhongzhi Qiu; Yang Lv; Guangmin Chen; Enyou Li
Journal:  J Clin Lab Anal       Date:  2020-11-04       Impact factor: 3.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.